Blood Test May Detect Pancreatic Cancer Earlier, Allow for ‘Meaningful Intervention’
The liquid biopsy uses three biomarkers and artificial intelligence, and researchers said it detected stage 1 and 2 disease 87% of the time.
- Researchers recently published a study in Nature Medicine involving 1,800 participants to evaluate PANXEON, a new blood test designed to detect pancreatic cancer in its early stages using artificial intelligence.
- Pancreatic cancer is often called a "silent" disease because symptoms typically emerge only at advanced stages, according to UCLA Health, leaving a five-year survival rate of just 13 percent.
- By screening for three molecular signatures, PANXEON uses artificial intelligence to assign a risk score. The test accurately detected stage 1 and 2 cancers approximately 87 percent of the time with low false-positive rates.
- Beyond cancer detection, the test identified high-grade dysplasia—a precancerous condition—more than 64 percent of the time in people with high-risk pancreatic cysts. This capability helps doctors determine who needs further evaluation.
- "A stage shift is not just a statistic," said Ajay Goel, PhD, AGAF, chair of City of Hope's department of molecular diagnostics and experimental therapeutics. Additional large-scale prospective studies remain necessary before clinical use.
21 Articles
21 Articles
One of the reasons why pancreatic cancer continues to be so lethal is that it is usually discovered late, after it has already spread. But this may be about to change. According to a new study published in the prestigious scientific journal Nature Medicine, a blood test developed by researchers led by the City of Hope, a leading institution in pancreatic cancer research in the United States, can detect the disease much earlier, when it is not on…
The liquid biopsy called PANXEON, which was presented in the context of international research, appears to have high sensitivity in detecting pancreatic cancer and precancerous lesions The post Pancreatic cancer: New blood test gives hope for early detection appeared first on in.gr.
The new method tested on 1,800 patients in the US, Europe and Asia uses biomarkers and AI to detect malignancy and precancerous lesions
In advanced pancreatic cancer, an ordinary blood count could indicate the progression of the disease, and it could also play a role in the choice of therapy.
Coverage Details
Bias Distribution
- 43% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
